Equity Profile

CRSP

CRISPR Therapeutics AG

Health CareBiotechnology$5.1B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

CRISPR Therapeutics AG is a biotechnology company focused on developing transformative gene-based medicines using CRISPR technology. As part of the healthcare sector, it aims to address serious diseases through innovative therapies, which could significantly impact patient care and treatment outcomes.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health, particularly important given its history of losses.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to scale its operations and commercialize its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRSP Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-4.69%

Avg Stock Reaction

-0.54%

Last Quarter Recap

In Q1 2026, CRISPR reported an EPS of -$1.28, missing estimates by 12.38%. Despite the loss, the stock rose 3.78% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for CRISPR's upcoming earnings are cautious, given its history of missing EPS estimates. Investors are keen to see if the company can show signs of revenue growth and improved financial performance.

Bull Case

The optimistic view hinges on potential positive news regarding new therapies or partnerships that could drive revenue growth and improve investor sentiment.

Bear Case

The pessimistic view focuses on the company's ongoing losses and the risk that it may continue to miss earnings expectations, leading to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of CRISPR's lead therapies and their potential for commercialization?

This will be crucial for understanding the company's revenue prospects and overall growth potential.

How does management plan to address the ongoing losses and improve profitability?

Investors will be looking for concrete plans or timelines that could signal a turnaround in financial performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for CRISPR's therapies to gain traction in the market, especially if recent clinical trial results are favorable.

Supporting Evidence

The stock has shown resilience despite poor earnings, indicating underlying investor confidence.

Options pricing suggests a significant move, which may reflect expectations for positive news that isn't fully appreciated by the market.

Key Risk

If CRISPR announces a successful trial or partnership, it could dramatically shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers on whether CRISPR can transition from research to revenue generation amidst ongoing financial challenges.

Bull Confirmed If

A clear path to commercialization for at least one therapy could validate the bull case.

Bear Confirmed If

Continued losses without a clear strategy for improvement would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±26.35%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±26.4% while CRSP has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

61.0%

Calls (499K)P/C Ratio: 0.53Puts (93K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRISPR beats expectations, history suggests a modest positive reaction, confirming that the company is on a path to recovery.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors weigh management's commentary.

Miss

A miss could lead to a significant decline, as history suggests an average drop when expectations are not met.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of lead therapies and any upcoming clinical trial results.
2Management's strategy for addressing ongoing financial losses.
3Details on partnerships or collaborations that could enhance revenue potential.
4Any guidance on future revenue expectations or timelines for commercialization.
5Insights into market demand for CRISPR's therapies based on recent developments.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health, particularly important given its history of losses.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to scale its operations and commercialize its therapies.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRSP Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-4.69%

Avg Stock Reaction

-0.54%

Last Quarter Recap

In Q1 2026, CRISPR reported an EPS of -$1.28, missing estimates by 12.38%. Despite the loss, the stock rose 3.78% the following day, indicating some investor optimism.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

The optimistic view hinges on potential positive news regarding new therapies or partnerships that could drive revenue growth and improve investor sentiment.

Bear Case

The pessimistic view focuses on the company's ongoing losses and the risk that it may continue to miss earnings expectations, leading to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of CRISPR's lead therapies and their potential for commercialization?

This will be crucial for understanding the company's revenue prospects and overall growth potential.

How does management plan to address the ongoing losses and improve profitability?

Investors will be looking for concrete plans or timelines that could signal a turnaround in financial performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for CRISPR's therapies to gain traction in the market, especially if recent clinical trial results are favorable.

Supporting Evidence

The stock has shown resilience despite poor earnings, indicating underlying investor confidence.

Options pricing suggests a significant move, which may reflect expectations for positive news that isn't fully appreciated by the market.

Key Risk

If CRISPR announces a successful trial or partnership, it could dramatically shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter centers on whether CRISPR can transition from research to revenue generation amidst ongoing financial challenges.

Bull Confirmed If

A clear path to commercialization for at least one therapy could validate the bull case.

Bear Confirmed If

Continued losses without a clear strategy for improvement would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±26.35%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±26.4% while CRSP has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

61.0%

Calls (499K)P/C Ratio: 0.53Puts (93K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CRISPR beats expectations, history suggests a modest positive reaction, confirming that the company is on a path to recovery.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors weigh management's commentary.

Miss

A miss could lead to a significant decline, as history suggests an average drop when expectations are not met.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of lead therapies and any upcoming clinical trial results.
2Management's strategy for addressing ongoing financial losses.
3Details on partnerships or collaborations that could enhance revenue potential.
4Any guidance on future revenue expectations or timelines for commercialization.
5Insights into market demand for CRISPR's therapies based on recent developments.